Development of dendritic-cell based prostate cancer vaccine

Immunology Letters

Volumn 74, Issue 1, 2000, Pages 87-93

  Tjoa, Benjamin A ^a   Murphy, Gerald P ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cells (DC); Immunotherapy; Metastatic; Prostate cancer; Prostate specific membrane antigen (PSMA); Responder

Indexed keywords

CANCER VACCINE; IMMUNOLOGICAL ADJUVANT;

ANTIGEN EXPRESSION; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; DENDRITIC CELL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; T LYMPHOCYTE ACTIVATION; VACCINATION;

EID: 0034666389     PISSN: 01652478     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2478(00)00254-6     Document Type: Article

References (67)

1. Hanks G., Krall J., Hanlon A., Asbell S., Pilepich M., Owen J. Patterns of care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. Int. J. Radiat. Oncol. Biol. Phys. 28:1994;39-45.
2. Middleton R., Smith J., Melzer R., Hamilton P. Patient survival and local recurrence rate following radical prostatectomy for prostatic carcinoma. J. Urol. 136:1986;422-424.
3. Walsh P.C., Partin A.W., Epstein J.I. Cancer control and quality of life following anatomic radical retropubic prostatectomy. Results at 10 years. J. Urol. 152:1994;1831-1836.
4. Ragde H. Brachytherapy (seed implantation) for clinically localized prostate cancer. J. Surg. Oncol. 64:1997;79-81.
5. Ragde H., Elgamal A., Snow P., Brandt J., Bartolucci A., Nadir B., Korb L. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer. 83:1998;989-1001.
6. G. Jones, C. Mettlin, G. Murphy, P. Guinan, H. Herr, D. Hussey, J. Chmiel, A. Fremgen, R. Clive, K. Zuber-Ocwieja, D. Winchester, Patterns of care for carcinoma of the prostate gland; results of a national survey of 1984 and 1990, J. Am. Coll. Surg. (1995) 545-554.
7. Oh W.K., Kantoff P.W. Management of hormone refractory prostate cancer: current standards and future prospects. J. Urol. 160:1998;1220-1229.
8. Iverson P. Orchidectomy and oestrogen therapy revisited. Eur. Urol. 34(Suppl.):1998;7-11.
9. Scher H.I., Steineck G., Kelly W.K. Hormone-refractory (D3) prostate cancer: refining the concept. Urology. 46:1995;142-148.
10. Krikorian J., Portlock C., Cooney D., Rosenberg S. Spontaneous regression of non-Hodgkin's lymphoma. A report of nine cases. Cancer. 46:1980;2093-2099.
11. Mitropoulos D., Kooi S., Rodriguez-Villanueva J., Platsoucas C.D. Charaterization of fresh (uncultured) tumour-inflitrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma. Clin. Exp. Immunol. 97:1994;321-327.
12. Ralfkiaer E., Hou-Jensen K., Gatter K., Drzewiecki D., Mason D. Immunohistological analysis of the lymphoid infiltrate in cutaneous malignant melanomas. Virchows Arch. 410:1987;355-361.
13. Ruiter D.J., Bhan A.K., Harrist T.J., Sober A.J., Mhim M. Jr Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferation and malignant melanoma. J. Immunol. 129:1982;2808-2815.
14. DeVita V. Jr Principles of chemotherapy. DeVita V. Jr, Hellman S., Rosenberg S. Cancer Principles & Practice of Oncology. 1997;276 Lippincott, Philadelphia.
15. Melder R.J., Whiteside T.L., Vujanovic N.L., Hiserodt J.C., Herberman R.B. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res. 48:1988;3461-3469.
16. Siegall C.B. Targeted toxins as anticancer agents. Cancer. 74:1994;1006-1012.
17. Rosenberg S.A., Packard B.S., Aebersold P.M., Solomon D., Topalian S.L., Toy S.T., Simon P., Lotze M.T., Yang J.C., Seipp C.A. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319:1988;1676-1680.
18. Topalian S., Solomon D., Avis F.P., Chang A.E., Freerksen D.L., Linehan W.M., Lotze M.T., Robertson C.M., Seipp C.A., Simon P. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6:1988;839-853.
19. Sedlacek H. Vaccination for treatment of tumors: a critical comment. Crit. Rev. Oncog. 5:1994;555-587.
20. Urban J.L., Schreiber H. Tumor antigens. Ann. Rev. Immunol. 10:1992;617-644.
21. Kappler J., Roehm N., Marrack P.T. Cell tolerance by clonal elimination in the thymus. Cell. 49:1987;273-280.
22. Foti A.G., Cooper J.F., Herschman H., Malvaez R.R. Detection of prostatic cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase. N. Engl. J. Med. 297:1977;1357-1361.
23. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., Heston D.W. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 54:1993;1807-1811.
24. Wang M., Valenzuela L., Murphy G., Chu T. Purification of a human prostate-specific antigen. Invest. Urol. 17:1979;159-163.
25. Slovin S.F., Kelly W.K., Scher H.I. Immunological approaches for the treatment of prostate cancer. Sem. Urol. Oncol. 16:1998;53-59.
26. Rosenberg S.A. Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J. Natl. Cancer Inst. 88:1996;1635-1644.
27. Marrack P., Kappler J. The T cell receptor. Science. 238:1987;1073-1079.
28. Zinkernagel R.M., Doherty P.C. Restriction of in vitro T cell-mediated cytotoxicity in lymphocytic choriomeningitis within a syngeneic or semiallogeneic system. Nature. 248:1974;701.
29. Engelhard V.H. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 12:1994;181-207.
30. Alexander M., Salgaller M.L., Celis E., Sette A., Barnes W.A., Rosenberg S.A., Steller M.A. Generation of tumor-specific cytolytic T lymphocytes from peripheral blood of cervical cancer patients by in vitro stimulation with a synthetic human papillomavirus type 16 E7 epitope. Am. J. Obstet. Gynecol. 175:1996;1586-1593.
31. Cormier J.N., Salgaller M.L., Prevette T., Barracchini K.C., Rivoltini L., Restifo N.P., Rosenberg S.A., Marincola F.M. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A [see comments]. Cancer J. Sci. Am. 3:1997;37-44.
32. Salgaller M.L., Marincola F.M., Cormier J.N., Rosenberg S.A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res. 56:1996;4749-4757.
33. Gupta R.K., Siber G.R. Adjuvants for human vaccines-current status, problems, and future prospects. Vaccine. 13:1995;1263-1276.
34. Fung P.Y.S., Madej M., Koganty R.R., Longenecker B.M. Active specific-immunotherapy of a murine mammary adenocarcinoma using a specific tumor-associated glycoconjugate. Cancer Res. 50:1992;4308-4311.
35. Gupta R.K., Varanelli C.L., Griffin P., Wallach D.F., Siber G.R. Adjuvant properties of non-phospholipid liposomes (Novasomes) in experimental animals for human vaccine antigens [published erratum appears in Vaccine Jun;14(8) (1996) 1]. Vaccine. 14:1996;219-225.
36. Helling F., Zhang S., Shang A., Adluri S., Calves M., Koganty R., Longenecker B.M., Yao T.J., Oettgen H.F., Livingston P.O. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res. 55:1995;2783-2788.
37. Ravindranath M.H., Morton D.L., Irie R.F. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy. Cancer Res. 49:1989;3891-3897.
38. Knight S.C., Stagg A.J. Antigen-presenting cell types. Curr. Opin. Immunol. 5:1993;374-382.
39. Mellman I., Turley S.J., Steinman R.M. Antigen processing for amateurs and professionals. Trends Cell Biol. 8:1998;231-237.
40. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., Engleman E.G., Levy R. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:1996;52-58.
41. Nestle F.O., Alijagic S., Gilliet M., Sun Y., Grabbe S., Dummer R., Burg G., Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:1998;328-332.
42. Murphy G.P., Tjoa B.A., Simmons S.J., Jarisch J., Bowes V.A., Ragde H., Rogers M., Elgamal A., Kenny G., Cobb O., Ireton R.C., Troychak M., Salgaller M.L., Boynton A.L. Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory prostate cancer. Prostate. 38:1999;73-78.
43. Murphy G.P., Tjoa B.A., Simmons S.J., Ragde H., Rogers M., Elgamal A., Kenny G.M., Troychak M.J., Salgaller M.L., Boynton A.L. Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment [in process citation]. Prostate. 39:1999;54-59.
44. Murphy G., Tjoa B., Ragde H., Kenny G., Boynton A. Phase I clinical trial: T cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate. 29:1996;371-380.
45. Tjoa B., Erickson S., Bowes V., Ragde H., Kenny G., Cobb O., Ireton R., Troychak M., Boynton A., Murphy G. Follow-up evaluation of prostate cancer patients with autologous dendritic cells pulsed with PSMA peptides. Prostate. 32:1997;272-278.
46. Tjoa B., Simmons S., Bowes V., Ragde H., Rogers M., Elgamal A., Kenny G., Cobb O., Ireton R., Troychack M., Salgaller M., Boynton A., Murphy G. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate. 36:1998;39-44.
47. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostate cells and serum of prostatic cancer patients. Anticancer Res. 7:1987;927-936.
48. Kawakami M., Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 15:1997;2321-2324.
49. Murphy G., Ragde H., Kenny G., Barren R. III, Erickson S., Tjoa B., Boynton A., Holmes E., Gilbauch J., Douglas T. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15:1995;1473-1480.
50. Austyn J. New insights into the mobilization and phagocytic activity of dendritic cells. J. Exp. Med. 180:1996;1287-1292.
51. Lindhout E., Figdor C.G., Adema G.J. Dendritic cells: migratory cells that are attractive. Cell Adhes. Commun. 6:1998;117-123.
52. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products [see comments]. J. Exp. Med. 182:1995;389-400.
53. Grabbe S., Beissert S., Schwarz T., Granstein R.D. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? [see comments]. Immunol. Today. 16:1995;117-121.
54. Young J.W., Steinman R.M. Dendritic cells stimulate primary human cytolytic lymphocyte response in the absence of CD4+ helper T cells. J. Exp. Med. 171:1990;1315-1332.
55. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9:1991;271-296.
56. Thomas R., Davis L.S., Lipsky P.E. Isolation and characterization of human peripheral blood dendritic cells. J. Immunol. 150:1993;821-829.
57. Berhard H., Disis M.L., Heimfeld S., Hand S., Gralow J.R., Cheever M.A. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood. Cancer Res. 55:1995;1099-1104.
58. N. Romani, D. Reider, M. Heuer, S. Ebner, E. Kempgen, B. Eibl, D. Niederwieser, G. Schuler, Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability, J. Immunol. Methods 196 (1996) 137-151.
59. Sallusto F., Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J. Exp. Med. 179:1994;1109-1118.
60. Tjoa B., Erickson S., Barren R. III, Ragde H., Kenny G., Boynton A., Murphy G. In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy. Prostate. 27:1995;63-69.
61. Maraskovsky E., McKenna H., Brasel K. In vivo administration of Flt3 ligand but not G-CSF nor GM-CSF results in the generation of large numbers of dendritic cells in mice. Blood. 86:1995;423a. Abstract 1680.
62. Knight S.C., Hunt R., Dore C., Medawar P.B. Influence of dendritic cells on tumor growth. Proc. Natl. Acad. Sci. USA. 82:1985;4495-4497.
63. Flamand V., Sornasse T., Thielemans K., Demanet C., Bakkus M., Bazin H., Tielemans F., Leo O., Urbain J., Moser M. Murine dendritic cells pulsed in vitro with tumor antigen induce tumur resistance in vivo. Eur. J. Immunol. 24:1994;605-610.
64. Grabbe S., Bruvers S., Gallo R.L., Knisely T.L., Nazareno R., Grandstein R.D. Tumor antigen presentation by murine epidermal cells. J. Immunol. 146:1991;3656-3661.
65. Mayordomo J.I., Zorina T., Storkus W.J., Zitvogel L., Celluzzi C., Falo L.D., Melief C.J., Ildstad S.T., Kast W.M., Deleo A.B. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1995;1297-1302.
66. Simmons S.J., Tjoa B.A., Rogers M., Elgamal A., Kenny G.M., Ragde H., Troychak M.J., Boynton A.L., Murphy G.P. GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate. 39:1999;291-297.
67. Tjoa B.A., Simmons S.J., Elgamal A., Rogers M., Ragde H., Kenny G.M., Troychak M.J., Boynton A.L., Murphy G.P. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 40:1999;125-129.